Anthera Pharmaceuticals, Inc. (ANTH)

[Paulieme]

Anthera Pharmaceuticals: Buy Low Opportunity On Potential Drug Approval
Feb. 2, 2016 8:51 AM ET| About: Anthera Pharmaceuticals, Inc. (ANTH)
Dave Dierking Dave Dierking+ Follow(713 followers)
Value, dividend investing, ETF investing, growth at reasonable price
Send Message|Website(201 clicks)
Summary

Anthera's lupus drug, Blisibimod, is in stage 3 clinical trial with results expected in the second half of 2016.

It also has its cystic fibrosis drug, Sollpura, in the clinical trial pipeline.

The stock was hurt late in 2015 following its second additional stock offering in the calendar year.

Zenyaku, its licensing and development partner in Japan, backed out of its deal in September 2015.

Citigroup recently reiterated its buy rating and $15 price target on Anthera's stock.

Anthera Pharmaceuticals (NASDAQ:ANTH) is a tiny biotech that trades primarily on hope at this point. The company's stock price moved significantly in 2015 and looked like it would be a top performer as it shot higher from $2 at the start of the year to a peak of over $11 in July as it announced it would release additional data on patient-reported outcomes of phase 2b PEARL-SC clinical trial of its leading drug candidate Blisibimod. The drug looks to treat the symptoms related to the onset of lupus.

The stock is currently trading back in the $3 range after the momentum of biotechs began cooling and the company needed to complete a second stock issue within the calendar year in order to raise funds for ongoing operations. It's a bit of a typical story for tiny biotech companies but if you begin looking towards what's in store throughout the remainder of 2016 there's a lot to like about Anthera.

Two drugs and five clinical studies underway

Anthera is currently developing two drugs.

Its lupus drug, Blisibimod, is in the midst of its phase 3 CHABLIS-SC1 clinical study after surpassing its 400 patient enrollment target in July of last year. The drug will also enter the phase 3 CHABLIS 7.5 trial shortly to study the effects of Blisibimod in the treatment of severe lupus symptoms not typically controlled with traditional medications. Anthera also has Blisibimod in the middle of a third middle stage clinical trial for treating IgA Nephropathy.

In September, Anthera initiated the phase 3 SOLUTION clinical study for its other drug, Sollpura, in treating cystic fibrosis patients. Another early stage clinical trial for the drug in treating pediatric cases is also being initiated.

page 1 / 3 | Next »
http://seekingalpha.com/article/3855466-anthera-pharmaceuticals-buy-low-opportunity-potential-drug-approval